These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 20455891

  • 1. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.
    Glass LC, Cusi K, Berria R, Petz R, Cersosimo E, Defronzo RA, Gastaldelli A.
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):339-45. PubMed ID: 20455891
    [Abstract] [Full Text] [Related]

  • 2. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 3. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 5. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
    Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E.
    Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
    [Abstract] [Full Text] [Related]

  • 6. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 9. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y, Matsuda M, DeFronzo RA.
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [Abstract] [Full Text] [Related]

  • 10. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 11. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 12. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
    Abdul-Ghani MA, Williams K, DeFronzo R, Stern M.
    Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
    [Abstract] [Full Text] [Related]

  • 13. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
    Yu X, Chen P, Wang H, Zhu T.
    Med Princ Pract; 2013 Jul; 22(2):156-60. PubMed ID: 22964975
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: differences between NGT, IFG, IGT, and type 2 diabetes mellitus. A cross-sectional and follow-up study.
    Pontiroli AE, Pizzocri P, Caumo A, Perseghin G, Luzi L.
    Acta Diabetol; 2004 Jun; 41(2):70-6. PubMed ID: 15224208
    [Abstract] [Full Text] [Related]

  • 15. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K.
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [Abstract] [Full Text] [Related]

  • 16. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 17. The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
    DeFronzo RA, Tripathy D, Abdul-Ghani M, Musi N, Gastaldelli A.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3774-81. PubMed ID: 24937535
    [Abstract] [Full Text] [Related]

  • 18. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
    Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA.
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1763-70. PubMed ID: 21411546
    [Abstract] [Full Text] [Related]

  • 19. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.
    Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group.
    Diabetes; 2002 Jul; 51(7):2170-8. PubMed ID: 12086947
    [Abstract] [Full Text] [Related]

  • 20. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?
    Radziuk J, Pye S.
    Diabetologia; 2006 Jul; 49(7):1619-28. PubMed ID: 16752180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.